Semaglutide, a glucagon like peptide-one (GLP-1) receptor agonist, is on the market as monotherapy in both equally subcutaneous in addition to oral dosage type (very first authorised oral GLP-1 receptor agonist). It's been accredited as a next line cure option for superior glycaemic Management in variety two diabetic issues and https://philq888bnw0.wikigdia.com/user